亚洲欧美精品在线-亚洲欧美精品中文字幕在线观看-亚洲欧美精品综合在线观看-亚洲欧美精选-亚洲欧美久久-亚洲欧美久久精品

Hello! Welcome to the official website of Betta Pharmaceuticals!
Service Hotline:+86-571-86130357     Add to Favorites | Online Feedback 中文

 


Bevacizumab (MIL60) is the third drug approved for marketing by Betta Pharmaceuticals and the first approved large molecule biologic.

In February 2017, Betta Pharmaceuticals entered into a collaboration with Beijing MAB Works Biotechnology Co., Ltd. for the bevacizumab injection project, and the entrusted manufacturer is Haizheng Biopharmaceutical Co., Ltd., a subsidiary of Zhejiang Borui Biopharmaceutical Co., Ltd.

In December 2019, the phase III clinical study of bevacizumab injection (MIL60) reached the primary study endpoint. It is a randomized, double-blind, multicenter Phase III study comparing the efficacy and safety of MIL60 in combination with paclitaxel and carboplatin to bevacizumab in combination with paclitaxel and carboplatin for the treatment of subjects with advanced or recurrent non-squamous non-small cell lung cancer (NSCLC) in primary treatment, led by Professor Wang Jie of Cancer Hospital of Chinese Academy of Medical Sciences with the participation of 50 research centers across China.

In June 2020, MIL60 marketing authorization application was accepted by the State Drug Administration.

In September 2021, MIL60 Phase III clinical research results were presented at the 2021 European Society of Medical Oncology (ESMO) Annual Meeting.

In November 2021, bevacizumab injection (MIL60) was officially approved for marketing, and the approved indications are metastatic colorectal cancer and advanced, metastatic or recurrent non-small cell lung cancer.

In December 2021, the results of bevacizumab research were published in EClinicalMedicine, a subjournal of The Lancet. Four new indications (recurrent glioblastoma; hepatocellular carcinoma; epithelial ovarian, fallopian tube or primary peritoneal carcinoma; and cervical cancer) were accepted for application.

In January 2022, the first order of bevacizumab was dispatched and the first prescriptions were written in several locations across China.

In March 2022, several new indications for bevacizumab (indications for the treatment of patients with recurrent glioblastoma, epithelial ovarian, fallopian tube or primary peritoneal cancer, and cervical cancer) were approved.


 

產品介紹.jpg



 


主站蜘蛛池模板: 久久久久久久久性生活 | 国产成人精品视频午夜 | 亚洲第一区第二区 | 亚洲美女影院 | 亚洲国产综合久久久无码色伦 | 粉嫩AV久久一区二区三区 | 成人毛片无码一区二区三区 | 一个人看的www片免费高清 | 久久国产精品亚洲国产女人 | 免费欧美久久精品国产一区二区 | 国产aⅴ精品一区二区三区久久 | 扒开双腿被两个男人玩弄视频 | 国产欧美精品一区二区三 | 在线日韩日本国产亚洲 | 99久久国产免费中文无字幕 | 2024亚洲天堂 | 免费欧美一区二区三区 | 亚洲国产精品自在自线观看 | 波多野结衣一区二区三区av免 | 日夜啪啪一区二区三区 | 国产精品长长久久 | 性xxxx欧美老妇胖老太性多毛 | 日本无卡v免费 | 美国毛片一级 | 无码专区人妻糸列日韩精品 | 亚洲中文字幕无码日韩 | 成人欧美一区二区三区视频 | 无码人妻精品一区二区三区久久久 | 手机在线看黄 | 2024国产在线视精品在 | 成年女人片免费播放视频 | 久久精品无码亚洲一区二区 | 手机看片国产欧美日韩高清 | 99免费吃奶五月激情狠狠干 | 青青青国产依人在线 | 国产交换精品一区二区三区免费 | 久久男人av资源网站无码软件 | 精品日产一卡二卡四卡 | 日本无吗不卡在线观看 | 久久久无码福利精品人妻一区 | 一级做a爰全过程免费视频毛片 |